Clinical Trials Browser

Frailty, Autoimmune Diseases, Chronic Disease, Neoplasms, Inflammatory Bowel Diseases, HIV Infections, Renal Insufficiency, Chronic

NCT05969821 2025-06-12

CHIS

Not yet recruiting

1,000 enrolled

LymphoidMyeloidOther hematologic neoplasm

VEXAS syndrome, Autoimmune Diseases, Hematologic Diseases, Immune System Diseases, Inflammation, Leukemia, Lymphoma, Lymphoproliferative Disorders, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Juvenile, Myelodysplastic-Myeloproliferative Diseases

NCT06827587 2025-02-14

Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

Phase NA Not yet recruiting

60 enrolled

Autoimmune Diseases, Myasthenia Gravis, Neuromuscular Diseases

NCT06723548 2024-12-09

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

Phase 4 Not yet recruiting

30 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT06567080 2024-08-22

JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases

Phase 1 Not yet recruiting

15 enrolled

Autoimmune Diseases, Lupus Erythematosus, Systemic

NCT06507800 2024-07-18

CATCH CANCER

Not yet recruiting

500 enrolled

Autoimmune Diseases, Neoplasms

NCT06416267 2024-05-16

MBL RiskConseq

Not yet recruiting

1,500 enrolled

LymphoidOther hematologic neoplasm

Alzheimer Disease, Autoimmune Diseases, Cardiovascular Diseases, Dementia, Infections, Neoplasms, Parkinson Disease, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

AMBU-VAX

CHIS

Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases

CATCH CANCER

MBL RiskConseq